Aakash Desai

Sep 4, 2024 | saintsmarching.com | Aakash Desai

In the away fixture against Thomas Frank's Brentford, Southampton faced another defeat in the Premier League after conceding three goals in the match. Although, the Saints were decent for most part of the game, defensive mistakes kept Russell Martin's side away from taking a draw in the third matchday. However, there was a big positive for Southampton towards the end of the match. The Saints haven't scored a Premier League goal since securing promotion from the Championship playoffs last season.

Aug 25, 2024 | newsbreak.com | Aakash Desai

By signing up for our newsletter, you agree to our Terms of Use and Privacy Policy

Aug 25, 2024 | targetedonc.com | Aakash Desai

Aakash Desai, MD, MPH, thoracic and phase 1 medical oncologist and assistant professor at the O’Neal Cancer Center at the University of Alabama, Birmingham, discusses the ADRIATIC study (NCT03703297) in limited-stage small cell lung cancer (LS-SCLC). The ADRIATIC study evaluated the use of durvalumab (Imfinzi) as consolidation treatment after concurrent chemoradiation in patients with LS-SCLC.

Jul 30, 2024 | onclive.com | Aakash Desai

CommentaryVideoJuly 30, 2024Author(s):akash Desai, MBBS, MPH, discusses unmet needs with the use of chemoimmunotherapy in patients with non–small cell lung cancer. Aakash Desai, MBBS, MPH, assistant professor, medicine, O'Neal Cancer Center, University of Alabama at Birmingham, discusses unmet needs with the treatment of chemoimmunotherapy in patients with non–small cell lung cancer (NSCLC), highlighting that patients will typically progress on this treatment approach.

Feb 15, 2024 | acsjournals.onlinelibrary.wiley.com | Aakash Desai |Caleb Smith |Joshua C. Pritchett |Konstantinos Leventakos

INTRODUCTION The advent of immune checkpoint inhibitor (ICI) therapy was initially shown to offer a significant overall survival (OS) benefit compared with docetaxel-based chemotherapy in chemotherapy-pretreated patients,1, 2 which led to Food and Drug Administration (FDA) approval by late 2015 as second-line or later treatment in patients with advanced non–small cell lung cancer (NSCLC).